Synthetic Approaches to the New Drugs Approved During 2020

New drugs introduced to the market are privileged structures that have affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody–drug conjugates (ADCs), provide insight into molecular recognition and s...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 65; no. 14; pp. 9607 - 9661
Main Authors Flick, Andrew C., Leverett, Carolyn A., Ding, Hong X., McInturff, Emma L., Fink, Sarah J., Mahapatra, Subham, Carney, Daniel W., Lindsey, Erick A., DeForest, Jacob C., France, Scott P., Berritt, Simon, Bigi-Botterill, Simone V., Gibson, Tony S., Watson, Rebecca B., Liu, Yiyang, O’Donnell, Christopher J.
Format Journal Article
LanguageEnglish
Published American Chemical Society 28.07.2022
Online AccessGet full text

Cover

More Information
Summary:New drugs introduced to the market are privileged structures that have affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody–drug conjugates (ADCs), provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This Review is part of a continuing series presenting the most likely process-scale synthetic approaches to 44 new chemical entities approved for the first time anywhere in the world during 2020.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.2c00710